Last reviewed · How we verify
Intravenous Fentanyl guided by SoC+NOL
Intravenous Fentanyl guided by SoC+NOL is a Opioid agonist Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Intraoperative analgesia and sedation during general anesthesia.
Intravenous fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation, with dosing guided by real-time monitoring of the nociceptive level (NOL index) combined with standard of care (SoC) assessment.
Intravenous fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation, with dosing guided by real-time monitoring of the nociceptive level (NOL index) combined with standard of care (SoC) assessment. Used for Intraoperative analgesia and sedation guided by nociceptive monitoring.
At a glance
| Generic name | Intravenous Fentanyl guided by SoC+NOL |
|---|---|
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Pain Management |
| Phase | FDA-approved |
Mechanism of action
Fentanyl is a synthetic opioid that activates mu-opioid receptors throughout the brain and spinal cord, reducing pain perception and producing sedation. The NOL (Nociceptive Level) index is a multiparametric monitor that measures physiological responses to nociception (pain stimulus) in real-time, allowing clinicians to titrate fentanyl dosing more precisely to match the patient's actual nociceptive burden rather than relying on standard dosing protocols alone. This guided approach aims to optimize analgesia while minimizing opioid exposure and adverse effects.
Approved indications
- Intraoperative analgesia and sedation during general anesthesia
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea and vomiting
- Chest wall rigidity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Fentanyl guided by SoC+NOL CI brief — competitive landscape report
- Intravenous Fentanyl guided by SoC+NOL updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI
Frequently asked questions about Intravenous Fentanyl guided by SoC+NOL
What is Intravenous Fentanyl guided by SoC+NOL?
How does Intravenous Fentanyl guided by SoC+NOL work?
What is Intravenous Fentanyl guided by SoC+NOL used for?
Who makes Intravenous Fentanyl guided by SoC+NOL?
What drug class is Intravenous Fentanyl guided by SoC+NOL in?
What development phase is Intravenous Fentanyl guided by SoC+NOL in?
What are the side effects of Intravenous Fentanyl guided by SoC+NOL?
What does Intravenous Fentanyl guided by SoC+NOL target?
Related
- Drug class: All Opioid agonist drugs
- Target: All drugs targeting Mu-opioid receptor (OPRM1)
- Manufacturer: Ciusss de L'Est de l'Île de Montréal — full pipeline
- Therapeutic area: All drugs in Anesthesia and Pain Management
- Indication: Drugs for Intraoperative analgesia and sedation during general anesthesia
- Compare: Intravenous Fentanyl guided by SoC+NOL vs similar drugs
- Pricing: Intravenous Fentanyl guided by SoC+NOL cost, discount & access